New Releases from NCBI BookshelfBimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy [Internet].Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy [Internet].
CADTH recommends that bimekizumab (Bimzelx) should be reimbursed by public drug plans for the treatment of adult patients with active […]
